|
1
|
Dzhauari S, Litvinova S, Efimenko A, Aleksandrushkina N, Basalova N, Abakumov M, Danilova N, Malkov P, Balabanyan V, Bezuglova T, Balayants V, Mnikhovich M, Gulyaev M, Skryabina M, Popov V, Stambolsky D, Voronina T, Tkachuk V, Karagyaur M. Urokinase-Type Plasminogen Activator Enhances the Neuroprotective Activity of Brain-Derived Neurotrophic Factor in a Model of Intracerebral Hemorrhage. Biomedicines 2022; 10:biomedicines10061346. [PMID: 35740368 PMCID: PMC9220139 DOI: 10.3390/biomedicines10061346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2022] [Revised: 05/31/2022] [Accepted: 06/06/2022] [Indexed: 11/30/2022] Open
Abstract
Brain-derived neurotrophic factor (BDNF) is a classic neuroprotective and pro-regenerative factor in peripheral and central nervous tissue. Its ability to stimulate the restoration of damaged nerve and brain tissue after ischemic stroke and intraventricular hemorrhage has been demonstrated. However, the current concept of regeneration allows us to assert that one factor, even if essential, cannot be the sole contributor to this complex biological process. We have previously shown that urokinase-type plasminogen activator (uPA) complements BDNF activity and stimulates restoration of nervous tissue. Using a model of intracerebral hemorrhage in rats, we investigated the neurotrophic and neuroprotective effect of BDNF combined with uPA. The local simultaneous administration of BDNF and uPA provided effective neuroprotection of brain tissue after intracerebral hemorrhage, promoted survival of experimental animals and their neurological recovery, and decreased lesion volume. The study of cellular mechanisms of the observed neurotrophic effect of BDNF and uPA combination revealed both known mechanisms (neuronal survival and neurite growth) and new ones (microglial activation) that had not been shown for BDNF and uPA. Our findings support the concept of using combinations of biological factors with diverse but complementary mechanisms of action as a promising regenerative approach.
Collapse
Affiliation(s)
- Stalik Dzhauari
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
| | - Svetlana Litvinova
- Federal State Budgetary Institution “Research Zakusov Institute of Pharmacology”, 8, Baltiyskaya Str., 125315 Moscow, Russia; (S.L.); (T.V.)
| | - Anastasia Efimenko
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
| | - Natalia Aleksandrushkina
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
| | - Nataliya Basalova
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
| | - Maxim Abakumov
- Department of Medical Nanobiotechnology, National University of Science and Technology MISiS, 4, Leninskiy Ave., 119049 Moscow, Russia;
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Pirogov Russian National Research Medical University, 1, Ostrovityanova Str., 117997 Moscow, Russia
| | - Natalia Danilova
- Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia; (N.D.); (P.M.); (D.S.)
| | - Pavel Malkov
- Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia; (N.D.); (P.M.); (D.S.)
| | - Vadim Balabanyan
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
| | - Tatiana Bezuglova
- Research Institute of Human Morphology, 3, Tsyurupy Str., 117418 Moscow, Russia; (T.B.); (V.B.); (M.M.)
| | - Viktor Balayants
- Research Institute of Human Morphology, 3, Tsyurupy Str., 117418 Moscow, Russia; (T.B.); (V.B.); (M.M.)
| | - Maxim Mnikhovich
- Research Institute of Human Morphology, 3, Tsyurupy Str., 117418 Moscow, Russia; (T.B.); (V.B.); (M.M.)
| | - Mikhail Gulyaev
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
| | - Mariya Skryabina
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
| | - Vladimir Popov
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
| | - Dmitry Stambolsky
- Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia; (N.D.); (P.M.); (D.S.)
| | - Tatiana Voronina
- Federal State Budgetary Institution “Research Zakusov Institute of Pharmacology”, 8, Baltiyskaya Str., 125315 Moscow, Russia; (S.L.); (T.V.)
| | - Vsevolod Tkachuk
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
| | - Maxim Karagyaur
- Faculty of Medicine, Lomonosov Moscow State University, 27/1, Lomonosovsky Ave., 119192 Moscow, Russia; (S.D.); (A.E.); (N.A.); (N.B.); (V.B.); (M.G.); (M.S.); (V.P.); (V.T.)
- Institute for Regenerative Medicine, Medical Research and Education Center, Lomonosov Moscow State University, 27/10, Lomonosovsky Ave., 119192 Moscow, Russia
- Correspondence:
| |
Collapse
|
|
2
|
Development of mode of action networks related to the potential role of PPARγ in respiratory diseases. Pharmacol Res 2021; 172:105821. [PMID: 34403731 DOI: 10.1016/j.phrs.2021.105821] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/04/2021] [Revised: 08/12/2021] [Accepted: 08/13/2021] [Indexed: 11/30/2022]
Abstract
The peroxisome proliferator-activated receptor γ (PPARγ) is a key transcription factor, operating at the intercept of metabolic control and immunomodulation. It is ubiquitously expressed in multiple tissues and organs, including lungs. There is a growing body of information supporting the role of PPARγ signalling in respiratory diseases. The aim of the present study was to develop mode of action (MoA) networks reflecting the relationships between PPARγ signalling and the progression/alleviation of a spectrum of lung pathologies. Data mining was performed using the resources of the NIH PubMed and PubChem information systems. By linking available data on pathological/therapeutic effects of PPARγ modulation, knowledge-based MoA networking at different levels of biological organization (molecular, cellular, tissue, organ, and system) was performed. Multiple MoA networks were developed to relate PPARγ modulation to the progress or the alleviation of pulmonary disorders, triggered by diverse pathogenic, genetic, chemical, or mechanical factors. Pharmacological targeting of PPARγ signalling was discussed with regard to ligand- and cell type-specific effects in the context of distinct disease inductor- and disease stage-dependent patterns. The proposed MoA networking analysis allows for a better understanding of the potential role of PPARγ modulation in lung pathologies. It presents a mechanistically justified basis for further computational, experimental, and clinical monitoring studies on the dynamic control of PPARγ signalling in respiratory diseases.
Collapse
|